Becton Dickinson and Company (BDX)
Becton Dickinson and Company (BDX) carries a ŷRobot AI score of 65 out of 100. The model's fair value estimate is $228.10, 4.6% above the last close of $218.04. The chart signal reads Sell.
| Metric | BDX |
|---|---|
| AI score | 65 / 100 |
| Chart signal | Sell |
| Fair value estimate | $228.10 |
| Upside to fair value | 4.6% |
| Previous close | $218.04 |
| P/E | 46.08 |
| Price / sales | 2.58 |
| Market cap | $58.76B |
| EPS | 4.54 |
| Revenue growth | 4.8% |
| 1-year price change | -3.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about BDX
Is BDX overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates Becton Dickinson and Company (BDX) at $228.10 against a last close of $218.04, implying 4.6% upside to the model's estimate.
Is BDX's chart signal bullish or bearish?
The chart-signal model classifies BDX as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is BDX's ŷRobot AI score?
BDX scores 65 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is BDX stock expensive on P/E and P/S?
BDX trades at 46.1 times earnings and 2.6 times sales as of Nov 13, 2026.
What does BDX's seasonal forecast show?
ŷRobot's seasonal forecast curve for BDX reads +0.3% at 30 days, +3.2% at 90 days, and -3.6% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BDX growing?
Becton Dickinson and Company's revenue growth is +4.8% and free-cash-flow growth is +12.3% on the latest reported figures.
BDX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.